In collaboration with the Strong, HIV positive, Empowered Women (SHE) programme, an industry-funded initiative aimed at improving the quality of life of HIV-positive women, Antiviral Therapy has taken the excellent step to dedicate a Supplement Issue addressing the needs and challenges related to the care of women living in Europe. Included articles present the multiple facets of gender-specific issues and research gaps, ranging from HIV testing strategies to antiretroviral combination therapy, including long-term challenges associated with chronic HIV infection.
JohnsonM., AfoninaL., HaanyamaO.The challenges of testing for HIV in women: experience from the UK and other European countries. Antivir Ther2013; 18Suppl 2: 19–25.
3.
SaagM.S., ChambersH.F., EliopoulosG.M., GilbertD.N., MoelleringR.C. (Editors). The Sanford Guide to HIV/AIDS therapy. 21st ed.Sperryville, VA: Antimicrobrial therapy, Inc.2013.
4.
MirallesC., MardarescuM., SherrL.What do we know about the situation of women living with HIV in Europe?Antivir Ther2013; 18Suppl 2: 11–17.
5.
StaehelinC., KeiserO., CalmyA.Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr2012; 59: 79–85.
6.
FordN., CalmyA., MofensonL.Safety of efavirenz in the first trimester of pregnancy. AIDS2011; 25: 2301–2304.
7.
World Health Organization.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Summary of key features and recommendations. Geneva. (Updated June 2013. Accessed 21 July 2013.) Available from http://apps.who.int/iris/bitstream/10665/85322/1/WHO_HIV_2013.7_eng.pdf.
8.
SibiudeJ., MandelbrotL., WarszawskiJ.Birth defects and ART in the French perinatal cohort, a prospective exhaustive study among 13,124 live births from 1994 to 2010.20th Conference on Retroviruses and Opportunistic Infections. 3–6 March 2013, Atlanta, GA, USA. Abstract 81.
9.
VernazzaP., HirschelB., BernasconiE., FleppM.Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull Med Suisse2008; 89: 165–169. French.
10.
CohenM.S., ChenY.Q., McCauleyM.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med2011; 365: 493–505.
11.
HaberlA., ReitterA.How does HIV affect the reproductive choices of women of childbearing age?Antivir Ther2013; 18: 35–44.
12.
RahangdaleL., CohnS., EllisP.Predictors of unplanned pregnancies among women living with HIV: US.20th Conference on Retroviruses and Opportunistic Infections. 3–6 March 2013, Atlanta, GA, USA. Abstract 896.
13.
d'Arminio MonforteA., GonzálezL., HaberlA.Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS2010; 24: 1091–1094.
14.
MolinaJ.M., CahnP., GrinsztejnB.Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a Phase 3 randomised double-blind active-controlled trial. Lancet2011; 378: 238–246.
15.
CohenC.J., Andrade-VillanuevaJ., ClotetB.Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a Phase 3, randomised, non-inferiority trial. Lancet2011; 378: 229–237.
16.
d'Arminio MonforteA., AndersonJ., OlczakA.What do we know about antiretroviral treatment of HIV in women?Antivir Ther2013; 18Suppl 2: 27–34.
17.
SquiresK.E., JohnsonM., YangR.Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother2011; 66: 363–370.
18.
RosinC., ElziL., ThurnherrC.Antiretroviral therapy in women: trends over 12 years in the Swiss HIV Cohort Study.13th European AIDS Conference. 12–15 October 2011, Belgrade, Serbia. Abstract PS11/4.
19.
WandelerG., KeiserO., HirschelB.A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society–USA. PLoS ONE2011; 6: e27903.
20.
MayM., GompelsM., DelpechV.Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ2011; 343: d6016.
21.
DominguezS., BrancoT., HaruperiT.Considerations for the long-term management of women living with HIV in Europe. Antivir Ther2013; 18Suppl 2: 45–52.
22.
YanJ., SoonG., ZhouS.Differences by age for women's response to initial HAART: meta-analysis of clinical trials submitted to the US Food and Drug Administration, 2000–2010.20th Conference on Retroviruses and Opportunistic Infections. 3–6 March 2013, Atlanta, GA, USA. Abstract 901.
23.
Abdool KarimQ., Abdool KarimS.S., FrohlichJ.A.Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science2010; 329: 1168–1174.
24.
MarrazzoJ., RamjeeG., NairG.Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003).20th Conference on Retroviruses and Opportunistic Infections. 3–6 March 2013, Atlanta, GA, USA. Abstract 26LB.
DruytsE., DybulM., KantersS.Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS2013; 27: 417–425.
27.
JohannessenA.Are men losers of the antiretroviral treatment scale-up?AIDS2011; 25: 1225–1226.
28.
CornellM., McIntyreJ., MyerL.Men and antiretroviral therapy in Africa: our blind spot. Trop Med Int Health2011; 16: 828–829.
